Focused On-demand Library for Mitochondrial coenzyme A transporter SLC25A42

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Solute carrier family 25 member 42

Alternative UPACC:

Q86VD7; D2T2J5; O14553; O43378


The Mitochondrial coenzyme A transporter SLC25A42, alternatively known as Solute carrier family 25 member 42, plays a crucial role in cellular energy metabolism. It facilitates the transport of coenzyme A (CoA) within mitochondria, exchanging it for intramitochondrial (deoxy)adenine nucleotides and adenosine 3',5'-diphosphate. This process is vital for numerous metabolic pathways, underscoring the protein's importance in maintaining cellular function.

Therapeutic significance:

SLC25A42 is implicated in a severe autosomal recessive disease characterized by muscle weakness, developmental delay, and encephalopathy, among other symptoms. The disease's variability in clinical manifestations, ranging from asymptomatic lactic acidosis to severe multiorgan involvement, highlights the protein's potential as a target for therapeutic intervention. Understanding the role of SLC25A42 could open doors to potential therapeutic strategies, offering hope for individuals affected by these metabolic crises.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.